IgA EGFR antibodies mediate tumour killing in vivo

Abstract

Currently all approved anti-cancer therapeutic monoclonal antibodies (mAbs) are of the IgG isotype, which rely on Fcgamma receptors (FcγRs) to recruit cellular effector functions. In vitro studies showed that targeting of FcαRI (CD89) by bispecific antibodies (bsAbs) or recombinant IgA resulted in more effective elimination of tumour cells by myeloid… (More)
DOI: 10.1002/emmm.201201929

Topics

Cite this paper

@inproceedings{Boross2013IgAEA, title={IgA EGFR antibodies mediate tumour killing in vivo}, author={Peter I Boross and Stefan Lohse and Maaike Nederend and Johannes Hendrik Marco Jansen and Geert van Tetering and Michael Dechant and Matthias Peipp and Louise Royle and Li Phing Liew and Louis Boon and Nico van van Rooijen and Wim W K Bleeker and Paul W H I Parren and Jan G. J. van de Winkel and Thomas Valerius and Jeanette H W Leusen}, booktitle={EMBO molecular medicine}, year={2013} }